No association of leukemia inhibitory factor (LIF) DNA polymorphisms with multiple sclerosis.
Neuropoietins such as leukemia inhibitory factor (LIF) have been shown to ameliorate experimental autoimmune encephalomyelitis (EAE) and promote oligodendrocyte survival in vivo. We tested whether two previously described LIF polymorphisms are associated with MS by genotyping these single nucleotide polymorphisms (SNPs) in a group of MS patients (n=110), rheumatoid arthritis (RA) patients (n=120) and healthy controls (HC, n=109). Similar allele and genotype frequencies for both SNPs were found for all study groups. Furthermore, no associations with MS type or HLA-DR2 expression could be found. In summary, no association was found between the studied LIF DNA polymorphisms and the prevalence of MS indicating that these polymorphisms are not involved in determining disease susceptibility.
Vanderlocht
Joris
J
Biomedical Research Institute, Hasselt University and Transnational University Limburg, Diepenbeek, Belgium.
Burzykowski
Tomasz
T
Somers
Veerle
V
Stinissen
Piet
P
Hellings
Niels
N
D000328:Adult; D000483:Alleles; D001172:Arthritis, Rheumatoid / Q000235:genetics; D004252:DNA Mutational Analysis; D005260:Female; D005787:Gene Frequency; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics*; D053605:Leukemia Inhibitory Factor; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000235:genetics*; D011110:Polymorphism, Genetic
D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor